| 摘要: |
| 目的：观察理冲汤加减联合紫杉醇+卡铂（TC） 方案治疗晚期卵巢癌的临床疗效及对患者血液流变学指标、免疫功能及肿瘤标志物水平的影响。方法：选取96例卵巢癌晚期患者，按随机数字表法分为对照组和观察组各48例。对照组给予TC方案治疗，观察组在对照组基础上给予理冲汤加减治疗，21 d为1个疗程，2组均治疗2个疗程。统计2组治疗前后的中医证候积分及治疗期间不良反应发生情况，检测血液流变学指标、T细胞亚群及肿瘤标志物水平，对比2 组临床疗效。结果：治疗后，2 组少腹包块、腹胀痛、面色无华及形体消瘦积分均较治疗前降低（P＜0.05），观察组上述4项中医证候积分均低于对照组（P＜0.05）。观察组疾病控制率77.08%，高于对照组的56.25%（P＜0.05）。观察组治疗有效率54.17%，对照组治疗有效率41.67%，2 组比较，差异无统计学意义（P＞0.05）。治疗后，2组血液流变学指标（全血黏度高切、全血黏度中切、全血黏度低切、血浆黏度） 水平均较治疗前降低（P＜0.05），观察组上述4项血液流变学指标水平均低于对照组（P＜0.05）。治疗后，观察组CD3+、CD4+、CD4+/CD8+水平均高于对照组（P＜0.05），CD8+水平低于对照组（P＜0.05）。治疗后，2组糖类抗原125（CA125）、糖类抗原19-9（CA19-9）、甲胎蛋白（AFP） 含量均较治疗前降低（P＜0.05），观察组CA125、CA19-9、AFP含量均低于对照组（P＜0.05）。观察组白细胞减少发生率6.25%，低于对照组的27.08%（P＜0.05）。2 组贫血、血小板减少、恶心呕吐、腹泻发生率比较，差异均无统计学意义（P＞0.05）。结论：理冲汤加减联合TC方案治疗晚期卵巢癌，可以有效改善患者的临床症状、血液流变学指标、免疫功能，降低肿瘤标志物水平，减少化疗产生的不良反应。 |
| 关键词: 卵巢癌 晚期 理冲汤 紫杉醇 卡铂 血液流变学 T细胞亚群 肿瘤标志物 |
| DOI： |
|
| 基金项目: |
|
| Clinical Study on Modified Lichong Tang Combined with TC Regimen for AdvancedOvarian Cancer |
| ZHOU Qin,ZHOU Fan,ZHANG Xiaohua |
| () |
| Abstract: |
| Abstract：Objective：To observe the clinical effect of modified Lichong tang combined with paclitaxel and carboplatin(TC)
regimen for advanced ovarian cancer， and its effect on hemorheological indexes， the immune function and the levels of
tumor markers. Methods：A total of 96 cases of patients with advanced ovarian cancer were divided into the control group and
the observation group according to the random number table method，48 cases in each group. The control group was treated
with TC regimen，and the observation group was additionally treated with modified Lichong tang based on the treatment of
the control group. Both groups were treated for two courses， 21 days being a course. The Chinese medicine syndrome
scores before and after treatment and the incidence of adverse reactions during treatment in the two groups were counted；
the levels of hemorheological indexes，T cell subsets and tumor markers were detected；the clinical effect was compared
between the two groups. Results： After treatment， the scores of masses in the lower abdomen， distending pain of
abdomen，dim complexion，and emaciation in the two groups were decreased when compared with those before treatment
(P＜0.05)， and the above four Chinese medicine syndrome scores in the observation group were lower than those in the
control group(P＜0.05). The disease control rate was 77.08% in the observation group， higher than that of 56.25% in the
control group(P＜0.05). The effective rate was 54.17% in the observation group， and 41.67% in the control group， there
being no significance in the difference(P＞0.05). After treatment，the levels of hemorheological indexes including whole blood
viscosity of high shear，middle shear and low shear，as well as plasma viscosity in the two groups were decreased when
compared with those before treatment(P＜0.05)，the above four levels in the observation group were lower than those in the
control group(P＜0.05). After treatment，the levels of CD8+ were decreased(P＜0.05)；the levels of CD3+，CD4+ and CD4+/
CD8 + in the observation group were higher than those in the control group(P＜0.05)，and the level of CD8 + was lower(P＜
0.05). After treatment，the contents of carbohydrate antigen 125(CA125)，carbohydrate antigen 19- 9(CA19- 9) and alphafetoprotein(
AFP) in the two groups were decreased when compared with those before treatment(P＜0.05)， and the above
three contents in the observation group were lower than those in the control group(P＜0.05). The incidence of leukopenia was
6.25% in the observation group， lower than that of 27.08% in the control group(P＜0.05). Compared the incidence of
anemia， thrombocytopenia， nausea and vomiting， and diarrhea， there being no significance in the difference(P＞0.05).
Conclusion： The therapy of modified Lichong tang combined with TC regimen in treating advanced ovarian cancer can
effectively improve the clinical symptoms，hemorheological indexes and the immune function，and reduce the level of tumor
markers and adverse reactions induced by chemotherapy. |
| Key words: Keywords：Ovarian cancer Advanced stage Lichong tang Paclitaxel Carboplatin Hemorheology T cell subsets Tumor markers |
